| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10967468 | Vaccine | 2013 | 9 Pages |
Abstract
Immunogenicity results of MnCCV-CRM197 for PCV13 compared with PCV7 included lower GMTs, but the clinical significance of this is unknown as the proportion of infants achieving protective MenC antibody titers was comparable in the two groups. Percent responders were similar up to titers of 1:128. PCV13 has an acceptable safety profile in infants and toddlers, while providing expanded coverage against pneumococcal disease.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Javier Diez-Domingo, Alejandra Gurtman, Enrique Bernaola, Francisco Gimenez-Sanchez, Federico Martinon-Torres, Valentin Pineda-Solas, Alfonso Delgado, Pilar Infante-Marquez, John Z. Liang, Peter C. Giardina, William C. Gruber, Emilio A. Emini,